Abstract
Digital contact tracing applications have been introduced in many countries to aid in the containment of COVID-19 outbreaks. Initially, enthusiasm was high regarding their implementation as a non-pharmaceutical intervention (NPI). Yet, no country was able to prevent larger outbreaks without falling back to harsher NPIs, and the total effect of digital contact tracing remains elusive. Based on the results of empirical studies and modeling efforts, we show that digital contact tracing apps might have prevented cases on the order of single-digit percentages up until now, at best. We show that this poor impact can be attributed to a combination of low participation rates, a non-flexible reliance on symptom-based testing, low engagement of participants, and delays between testing and test result upload. We find that contact tracing does not change the epidemic threshold and exclusively prevents more cases during the supercritical phase of an epidemic, making it unfit as a tool to prevent outbreaks. Locally clustered contact structures may increase the intervention’s efficacy, but only if the number of contacts per individual is homogeneously distributed, a condition usually not found in contact networks. Our results suggest that policy makers cannot rely on digital contact tracing to contain outbreaks of COVID-19 or similar diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
BFM is supported as an Add-On Fellow for Interdisciplinary Life Science by the Joachim Herz Stiftung.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No empirical data has been collected in this study.
